Article
Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2015
Starmans Maud H W, Pintilie Melania, Chan-Seng-Yue Michelle, Moon Nathalie C, Haider Syed, Nguyen Francis, Lau Suzanne K, Liu Ni, Kasprzyk Arek, Wouters Bradly G, Der Sandy D, Shepherd Frances A, Jurisica Igor, Penn Linda Z, Tsao Ming-Sound, Lambin Philippe, Boutros Paul C
Abstract excerpt
PURPOSE: While the dysregulation of specific pathways in cancer influences both treatment response and outcome, few current prognostic markers explicitly consider differential pathway activation. Here we explore this concept, focusing on K-Ras mutations in lung adenocarcinoma (present in 25%-35% of patients). EXPERIMENTAL DESIGN: The effect of K-Ras mutation status on prognostic accuracy of existing signatures...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.